MaxCyte, Inc
Gaithersburg, MD 20878
Share:
Scalable System customizes stem cells for therapeutic use.
GT(TM) Flow Transfection System enables accelerated and efficient transfection of any primary cell or cell line with greater than 90% cell viability following loading with range of molecules - proteins, drugs, plasmids, mRNA, miRNA, siRNA - or combinations thereof at volumes up to tens of billion cells. With processing time of under 30 min, solution enables consistent cGMP-compliant cell...
Read More »MaxCyte and KSQ Therapeutics Announce Development and Commercialization Agreement to Enable the Advancement of KSQ's Adoptive Cell Therapy Programs
GAITHERSBURG, Md. and CAMBRIDGE, Mass., Dec. 4, 2019 /PRNewswire/ -- MaxCyte, the global cell-based therapies and life sciences company, and KSQ Therapeutics, a biotechnology company using its proprietary CRISPRomics® discovery platform to achieve higher probabilities of success in drug development, announced today that the companies have entered into a new development and commercialization...
Read More »Scalable System customizes stem cells for therapeutic use.
GT(TM) Flow Transfection System enables accelerated and efficient transfection of any primary cell or cell line with greater than 90% cell viability following loading with range of molecules - proteins, drugs, plasmids, mRNA, miRNA, siRNA - or combinations thereof at volumes up to tens of billion cells. With processing time of under 30 min, solution enables consistent cGMP-compliant cell...
Read More »